vs
Side-by-side financial comparison of COMERICA INC (CMA) and Moderna (MRNA). Click either name above to swap in a different company.
Moderna is the larger business by last-quarter revenue ($1.0B vs $838.0M, roughly 1.2× COMERICA INC). COMERICA INC runs the higher net margin — 21.0% vs -19.7%, a 40.7% gap on every dollar of revenue. On growth, COMERICA INC posted the faster year-over-year revenue change (3.3% vs -45.4%). Over the past eight quarters, COMERICA INC's revenue compounded faster (108.9% CAGR vs -45.0%).
Comerica Incorporated is an American financial services company, headquartered in Dallas, Texas. It is the parent of Comerica Bank, a regional commercial bank with 413 branches in the U.S. states of Texas, Michigan, California, Florida and Arizona. Comerica is among the largest U.S. financial holding companies, with offices in a number of U.S. cities.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
CMA vs MRNA — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $838.0M | $1.0B |
| Net Profit | $176.0M | $-200.0M |
| Gross Margin | — | 79.6% |
| Operating Margin | — | -25.6% |
| Net Margin | 21.0% | -19.7% |
| Revenue YoY | 3.3% | -45.4% |
| Net Profit YoY | -4.3% | -1638.5% |
| EPS (diluted) | $1.35 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $838.0M | $1.0B | ||
| Q2 25 | $849.0M | — | ||
| Q1 25 | $829.0M | — | ||
| Q4 24 | $825.0M | $966.0M | ||
| Q3 24 | $811.0M | $1.9B | ||
| Q2 24 | $824.0M | — | ||
| Q1 24 | $784.0M | — | ||
| Q4 23 | $192.0M | $2.8B |
| Q3 25 | $176.0M | $-200.0M | ||
| Q2 25 | $199.0M | — | ||
| Q1 25 | $172.0M | — | ||
| Q4 24 | $170.0M | $-1.1B | ||
| Q3 24 | $184.0M | $13.0M | ||
| Q2 24 | $206.0M | — | ||
| Q1 24 | $138.0M | — | ||
| Q4 23 | $33.0M | $217.0M |
| Q3 25 | — | 79.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 67.0% |
| Q3 25 | — | -25.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -129.0% | ||
| Q3 24 | — | -3.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 0.2% |
| Q3 25 | 21.0% | -19.7% | ||
| Q2 25 | 23.4% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 20.6% | -115.9% | ||
| Q3 24 | 22.7% | 0.7% | ||
| Q2 24 | 25.0% | — | ||
| Q1 24 | 17.6% | — | ||
| Q4 23 | 17.2% | 7.7% |
| Q3 25 | $1.35 | $-0.51 | ||
| Q2 25 | $1.42 | — | ||
| Q1 25 | $1.25 | — | ||
| Q4 24 | $1.22 | $-2.91 | ||
| Q3 24 | $1.33 | $0.03 | ||
| Q2 24 | $1.49 | — | ||
| Q1 24 | $0.98 | — | ||
| Q4 23 | $0.20 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.1B |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $7.4B | $9.3B |
| Total Assets | $77.4B | $12.1B |
| Debt / EquityLower = less leverage | 0.73× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $2.9B |
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.8B | — | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $6.7B | — | ||
| Q3 24 | $6.8B | — | ||
| Q2 24 | $7.1B | — | ||
| Q1 24 | $7.1B | — | ||
| Q4 23 | $6.2B | — |
| Q3 25 | $7.4B | $9.3B | ||
| Q2 25 | $6.9B | — | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $6.5B | $10.9B | ||
| Q3 24 | $7.4B | $11.9B | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.0B | — | ||
| Q4 23 | $6.4B | $13.9B |
| Q3 25 | $77.4B | $12.1B | ||
| Q2 25 | $78.0B | — | ||
| Q1 25 | $77.6B | — | ||
| Q4 24 | $79.3B | $14.1B | ||
| Q3 24 | $79.7B | $15.8B | ||
| Q2 24 | $79.6B | — | ||
| Q1 24 | $79.4B | — | ||
| Q4 23 | $85.8B | $18.4B |
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.92× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.18× | — | ||
| Q4 23 | 0.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-270.0M | $-847.0M |
| Free Cash FlowOCF − Capex | — | $-880.0M |
| FCF MarginFCF / Revenue | — | -86.6% |
| Capex IntensityCapex / Revenue | — | 3.2% |
| Cash ConversionOCF / Net Profit | -1.53× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-270.0M | $-847.0M | ||
| Q2 25 | $476.0M | — | ||
| Q1 25 | $273.0M | — | ||
| Q4 24 | $601.0M | $825.0M | ||
| Q3 24 | $1.0B | $-1.6B | ||
| Q2 24 | $111.0M | — | ||
| Q1 24 | $-205.0M | — | ||
| Q4 23 | $1.1B | $622.0M |
| Q3 25 | — | $-880.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $303.0M | ||
| Q3 24 | — | $-1.7B | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $402.0M |
| Q3 25 | — | -86.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 31.4% | ||
| Q3 24 | — | -92.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 14.3% |
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 8.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 7.8% |
| Q3 25 | -1.53× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 5.70× | -120.46× | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | -1.49× | — | ||
| Q4 23 | 34.00× | 2.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMA
Segment breakdown not available.
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
